OX1 Receptor Antagonists Patent Application

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published May 9th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a new patent application (US20260085056A1) filed on May 9, 2025, by NXERA PHARMA UK LIMITED. The application relates to novel compounds for treating neurological or psychiatric disorders associated with orexin receptors.

View original document View source feed page

What changed

This document is a publication of a new patent application, US20260085056A1, filed by NXERA PHARMA UK LIMITED on May 9, 2025. The application discloses novel compounds of formula (I) and their use in treating neurological or psychiatric disorders associated with orexin receptors.

As this is a patent application publication, it does not impose new regulatory obligations or compliance deadlines on regulated entities. It serves as a notice of intellectual property filing related to pharmaceutical research and development in the area of neurological and psychiatric disorders.

Source document (simplified)

← USPTO Patent Applications

OX1 RECEPTOR ANTAGONISTS

Application US20260085056A1 Kind: A1 Mar 26, 2026

Assignee

NXERA PHARMA UK LIMITED

Inventors

Giles Albert BROWN, Miles Stuart CONGREVE, John Andrew CHRISTOPHER, Nigel Alan SWAIN, Sarah Joanne BUCKNELL, Anne Mary STEPHENSON, Benjamin Gerald TEHAN, Mark MILLS, Anil PATEL

Abstract

The disclosures herein relate to novel compounds of formula (I); and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.